Beijing Top Grade Medical Equipment Company and SBI Pharmaceuticals Co., Ltd.
Beijing, China and Tokyo, Japan
Beijing Top Grade Medical Equipment Company (“Top Grade”) and Fox Chase Cancer Center entered into a partnership under which Fox Chase will use a specialized accelerator (Racetrack Microtron) available from Top Grade to treat late-stage cancer patients who are no longer responding to conventional therapies. The treatment consists of radiation therapy with very high energy photon beams, in conjunction with a photosensitizing drug (5-Aminolevulinic acid [ALA]).
SBI Pharmaceuticals Co., Ltd. Headquartered in Tokyo, Japan, through its US subsidiary NX Development Corporation (NXDC), recently received FDA approval for use of its flagship product Gleolan™ (ALA hydrochloride), an optical imaging agent indicated in patients with high-grade gliomas as an adjunct for the visualization of malignant tissue during surgery. Fox Chase also partnered with NXDC for use of its ALA as the photosensitizing agent in evaluating this novel approach to cancer treatment.
About Our Partnership
A Phase I study using the Racetrack Microtron in combination with ALA in advanced malignancies for whom no standard therapy is available will be available at Fox Chase by 2020.
